Human ANG-1 Recombinant Protein LyophilizedIHUANG1RLY5UG
Human ANG-1 Recombinant Protein Lyophilized from Innovative Research has been recombinantly produced in HeLa cells. This is a Lyophilized protein buffered in with a purity of Greater than 95% by SDS-PAGE gel and HPLC analyses.
Endotoxin level is less than 0.1 ng per and#956;g (1EU/and#956;g)..
- Species: Human
- Target: ANGPT1
Purity: Greater than 95% by SDS-PAGE gel and HPLC analyses.
Endotoxin level is less than 0.1 ng per and#956;g (1EU/and#956;g).
- Source: HeLa cells
- Storage Conditions: The lyophilized ANG-1 recombinant protein is stable for at least 2 years from date of receipt at -20°C. Reconstituted ANG-1 is stable for at least 3 months when stored in working aliquots with a carrier protein at -20°C. As with any protein, exposing ANG-1 recombinant protein to repeated freeze / thaw cycles is not recommended. When working with proteins care should be taken to keep recombinant protein at a cool and stable temperature.
Angiopoietin-1 (Ang-1) is a secreted ligand for Tie-2, a tyrosine-kinase receptor expressed primarily on vascular endothelial cells and early hematopoietic cells. Ang-1/ Tie-2 signaling promotes angiogenesis during the development, remodeling, and repair of the vascular system. Transgenic mice lacking expression of either Ang-1 or Tie-2 fail to develop a fully functional cardiovascular system and die before birth. Postnatally, the angiogenic activity of Ang-1/Tie-2 is required during normal tissue repair and remodeling of the female endometrium in the menstrual cycle. Ang-1/Tie-2 signaling appears to be regulated by Angiopoietin-2 (Ang-2), a natural anTagonist for Tie-2 that exerts its effects through an internal autocrine loop mechanism. In addition to suppressing endothelial cell activation by inhibiting the expression of adhesion and inflammatory molecules, Ang-1 enhances endothelial cell survival and capillary morphogenesis, and lessens capillary permeability. As such, Ang-1 has a potential to become an effective therapeutic agent for treating various endothelium disorders, including several severe human pulmonary diseases. The efficacy of cell-based Ang-1 gene therapy for acute lung injury (ALI) has recently been studied in a rat model of ALI (1). The results of this study show that such therapy can markedly improve lung condition and suggest that Ang-1 therapy may represent a potential new strategy for the treatment and/or prevention of acute respiratory distress injury (ARDI), a significant cause of morbidity and mortality in critically ill patients. Recombinant human ANG-1, derived from HeLa cells, is a C-terminal histidine Tagged glycoprotein which migrates with an apparent molecular mass of 60.0 - 70.0 kDa by SDS-PAGE under reducing conditions. Sequencing analysis shows N-terminal sequences starting with Ser-20 and with Asp-70 of the 498 amino acid precursor protein.
. At Innovative Research we provide reliable, consistent products that deliver reliable, consistent results.
This material is sold for in-vitro use only for manufacturing and research. This material is not suitable for human or animal use. While we make every effort to ensure the safety of our products, we recommend handling any biological materials with standard precautions as if capable of spreading infectious disease. The statements herin are offered for informational purposes only to be used solely for your consideration, investigation, and verification.
Please be aware the image pictured is for illustrative purposes only, and your product packaging and appearance may vary.
Get in touch with our team! Please include any relevant information (product name, etc)